BioSpace News Archive

Activ Surgical™, a digital surgery pioneer, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,925,465 B2 for the company’s ActivSight enhanced visualization module

Bright Peak Therapeutics Inc., a biotechnology company developing next generation immunotherapies for cancer and autoimmune disease, and Ajinomoto Co., Inc. (“Ajinomoto Co.”), a leading technology provider for biopharmaceuticals and the owner of Ajinomoto Bio-Pharma Services offering pharmaceutical contract development and manufacturing services, today announced a research collaboration and exclusive license agreement to incorporate AJICA

Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment of US$190 million investment from institutional investors, and over $100 million investment has already been closed today

AmerisourceBergen Corporation (NYSE: ABC) today announced that it priced $1.525 billion aggregate principal amount of its 0.737% Senior Notes due March 15, 2023 (the “2023 Notes”) and $1.0 billion aggregate principal amount of its 2.700% Senior Notes due March 15, 2031

The incidences of chronic diseases, contagious infections, and viruses are increasing rapidly. The healthcare sector is making swift advancements in this aspect.

Sterilization refers to a method of eliminating biological agents such as bacteria, fluids, unicellular eukaryotic organisms, unicellular eukaryotic organisms, and spore forms.

Antengene Corporation Limited (“Antengene” or “the company”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced its annual financial results for the full year ending December 31, 2020

Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a public offering price of $16.00 per share.

Edgewise Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced the pricing of its underwritten initial public offering of 11,000,000 shares of its common stock at a public offering price of $16.00 per share.

Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of $20.00 per share.